U.S. stock market midday update: Alps stock price plummets 14.04%, trading volume surges, what is causing such volatility in market sentiment?

U.S. Stock Market Midday Update

Alps, down 14.04%, with increased trading volume and no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Stocks with High Trading Volume in the Industry

bioAffinity Tech, up 109.81%, with a trading volume of $494 million, and a 10-day increase of 111.79%, with no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

AbbVie, down 1.10%, with a trading volume of $454 million and increased trading volume, with no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Gilead Sciences up 1.01%. Based on recent key news:

1. On March 11, Gilead Sciences outperformed the market with an annualized return of 11.88%. This stable growth has attracted investor attention, driving the stock price up.

2. On March 11, trial results for Gilead Sciences' HIV treatment showed positive effects, with a new single-tablet regimen being very effective in maintaining viral suppression, enhancing market confidence in its product line.

3. On March 11, Gilead Sciences' strong dividend plan and robust product pipeline, especially in oncology, are expected to drive future sales growth, further supporting stock price increases. The biopharmaceutical industry has significant growth potential, with noticeable capital inflows.

Stocks with High Market Capitalization in the Industry

Amgen up 0.34%. Based on recent key news:

1. On March 12, market analysts maintained a "hold" rating on Amgen, despite other stocks being recommended as better investment choices. This indicates limited market confidence in Amgen, which may affect its stock price increase. Source: MarketBeat

2. On March 11, Senate Democrats pressured pharmaceutical companies to disclose how secret agreements made with the Trump administration lowered drug costs. This may impact Amgen's pricing strategy and subsequently affect its market performance. Source: United States Senate Committee on Finance The pharmaceutical industry faces policy pressure, with significant capital inflows